Biotech Company Developing Stem Cell Therapy for Diabetes
Advanced Islet Cell Technology
Scalable ILC Cell Products
Ethical Innovation
Cutting Edge Research
Regenerative Medical Solutions (RMS)
Imagine a future where diabetic patients no longer rely on insulin injections to survive. Our groundbreaking stem cell therapy for diabetes is turning this vision into reality.
Regenerative Medical Solutions (RMS) is a biotech company developing a functional cure for diabetes. Our revolutionary approach leverages stem cell therapy to enable diabetic patients to produce the insulin they need. We invite biotech investors, pharmaceutical experts, and anyone passionate about diabetes research to join us in bringing our life-changing cure to market. Together, we can bring this breakthrough to the millions who need it and redefine what’s possible in diabetes treatment.
Contact RegenMed Solutions to learn more about the lives you could change, and the return on investment you could see.
A Cure for Diabetes Starts Here
RMS is pioneering a cutting-edge prospective diabetes cure, leveraging regenerative medicine to restore pancreatic function at the cellular level and eliminating insulin-dependency.
A Functional Cure for Diabetes
Our new stem cell therapy is a prospective cure for diabetes that works by transforming stem cells into insulin-producing cells.
A Scalable Solution
Our innovative stem cell therapy for diabetes is designed to be scalable.
An Affordable Alternative
Our goal is to create an affordable cure for diabetes that’s suitable for the majority of patients and widespread commercialization.
RMS vs Other Diabetes Treatments
There is a gap in the market for a diabetes treatment that goes beyond symptom management and is accessible to the wider diabetic community, and the need is growing.
- Insulin injections are the most common diabetes treatment today, but they only manage symptoms without providing a cure.
- Diabetes can also be cured with islet transplant surgery. However, this relies on organ donation and cannot be scaled to treat all patients.
Our potential diabetes cure also stands out from the other solutions currently in clinical trials:
- Unlike other diabetes treatments currently in trials, our prospective cure doesn’t require the use of heavy immunosuppressive drugs.
- We don’t use cells derived from human embryos in our diabetes research.
- Our stem cell therapy is designed for all blood types.
- Our work has applications for type 1 and type 2 diabetes.
- Our solution doesn’t require the use of an implantable device.
Why Invest in Our Stem Cell Therapy for Diabetes?
Our stem cell therapy for diabetes is currently progressing through clinical trials, creating a rare opportunity for investors to act now and be part of medical history. Our prospective diabetes cure is:
- Backed by over two decades of research.
- Designed to be scalable and affordable.
- Could eliminate the need for insulin injections.
- Utilizes outstanding intellectual property.
- Offers significant return on investment potential.
Partnering with RMS: Biotech Company & Pharmaceutical Collaborations
We’re passionate about ensuring our diabetes research has the most positive impact. Therefore, we’re open to working with pharmaceutical and biotech companies to bring our prospective diabetes cure to market faster and make life-changing regenerative medicine more accessible.
We encourage biotechnology companies and pharmaceutical manufacturers to reach out about strategic acquisition and research and development opportunities.
Other Applications for our iPSC Stem Cell Technology
The regenerative medicine developed by our biotechnology company has great potential for stem cell therapy for diabetes and more.
- Our primary goal is to develop a cure for type 1 and type 2 diabetes.
- Our ILC Cell Kit and ProgenMix™ media formulation are designed to help other biotech companies cultivate pancreatic cells more efficiently.
- For pharmaceutical and biotech companies, we offer customizable biotech consulting services in the fields of stem cell and diabetes research.
About Regenerative Medical Solutions: An Innovative Biotech Company
Regenerative Medical Solutions, Inc., is a biotech startup originating from Dr. Jon Odorico’s laboratory’s academic research at the University of Wisconsin. Our company is also referred to as RegenMed Solutions, or RMS.
Dr. Odorico is a world-renowned researcher who started working at the University of Wisconsin Hospital in 1995. As a pancreatic replacement surgeon, Dr. Odorico was very familiar with the shortage of donor pancreases. He conducted extensive research concentrated on using stem cells to replicate the function of the pancreas. When Dr. Odorico’s daughter was diagnosed with type 1 diabetes in 2006, he expanded his research, gaining patent after patent.
RegenMed Solutions was founded in 2012 with a vision to harness the regenerative property of human induced pluripotent stem cells (iPSCs) to produce pancreatic β (beta) islet cells to cure diabetes. RMS is a privately-owned biotechnology company operating near Madison, Wisconsin. We are a team of experts and renowned stem cell researchers developing a protocol to grow healthy and resilient pancreatic cells. Our leadership team has vast experience successfully growing start-ups and technology companies.
Help Find a Diabetes Cure
Invest and potentially change the future by playing your part in the development of our new stem cell therapy for diabetes. Biotech companies, venture capitalists and investors are key to our progress; we welcome you to get in touch to learn more.